6. パーキンソン病 Parkinson disease Clinical trials / Disease details

臨床試験数 : 2,298 / 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

1020 trials found

diseases per page:

Showing 1 to 10 of 1,020 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04147949 (ClinicalTrials.gov)	August 2022	27/10/2019	AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia	Randomized, Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Phase 2 Study to Test Effi ...	Parkinson Disease;Dyskinesia, Medication-Induced;L-Dopa Causing Adverse Effects in Therapeutic Use	Drug: AV-101;Drug: Placebo	VistaGen Therapeutics, Inc.	NULL	Not yet recruiting	30 Years	80 Years	All	20	Phase 2	NULL
2	NCT05258071 (ClinicalTrials.gov)	March 2022	10/2/2022	A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Di ...	A Randomised, Placebo-controlled, Multicentre Phase IIb Study Evaluating the Efficacy of Pirepemat o ...	Parkinson Disease	Drug: Pirepemat;Drug: Placebo	Integrative Research Laboratories AB	NULL	Not yet recruiting	55 Years	85 Years	All	165	Phase 2	NULL
3	NCT05287503 (ClinicalTrials.gov)	February 15, 2022	28/1/2022	Ambroxol as a Disease-modifying Treatment in GBA-PD	Ambroxol as a Disease-modifying Treatment to Reduce the Risk of Cognitive Impairment in GBA-associat ...	Parkinson Disease;GBA Gene Mutation	Drug: Ambroxol Hydrochloride;Drug: Placebo	Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta	University of Campania Luigi Vanvitelli;IRCCS National Neurological Institute C. Mondino Foundation	Recruiting	21 Years	80 Years	All	60	Phase 2	Italy
4	NCT05266417 (ClinicalTrials.gov)	February 7, 2022	23/2/2022	Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Evaluate the Safety, Tolerability, ...	Parkinson Disease	Drug: INS-GSH;Drug: Matched Placebos	Gateway Institute for Brain Research	NULL	Recruiting	30 Years	85 Years	All	56	Phase 2	United States
5	NCT04831281 (ClinicalTrials.gov)	January 20, 2022	1/4/2021	ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE ...	A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Parkinso ...	Parkinson Disease Dementia;Dementia With Lewy Bodies	Drug: ATH-1017;Drug: Placebo	Athira Pharma	NULL	Recruiting	40 Years	85 Years	All	75	Phase 2	United States
6	NCT03446807 (ClinicalTrials.gov)	December 2021	20/2/2018	Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism	Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism	Parkinson Disease;Multiple System Atrophy;Progressive Supranuclear Palsy	Drug: Droxidopa;Drug: Placebo Oral Tablet	Loma Linda University	H. Lundbeck A/S	Not yet recruiting	50 Years	N/A	All	32	Phase 2	United States
7	NCT04944017 (ClinicalTrials.gov)	November 23, 2021	22/6/2021	Ketamine for the Treatment of Depression in Parkinson's Disease	Ketamine for the Treatment of Depression in Parkinson's Disease	Parkinson's Disease;Depression	Drug: Ketamine Infusion;Other: Placebo - Saline Infusion	Yale University	Fox (Michael J.) Foundation for Parkinson's Research	Recruiting	40 Years	70 Years	All	56	Phase 2	United States
8	NCT05173701 (ClinicalTrials.gov)	November 22, 2021	8/11/2021	Effects of Probiotics on Peripheral Immunity in Parkinson's Disease	Effects of Probiotics on Peripheral Immunity in Parkinson's Disease	Parkinson's Disease	Dietary Supplement: Probiotics;Dietary Supplement: Placebo	Franca Marino	Università degli Studi del Piemonte Orientale Amedeo Avogadro;Università degli Studi dell'Insubria	Enrolling by invitation	N/A	N/A	All	88	N/A	Italy
9	NCT05056194 (ClinicalTrials.gov)	November 1, 2021	17/9/2021	Valiloxybate (XW10172 MR) Efficacy and Safety Parkinson's Disease Study	A Double-blind, Randomized, Placebo-controlled, Parallel, Study to Assess the Efficacy and Safety of ...	Parkinson Disease;Excessive Daytime Somnolence	Drug: Valiloxybate;Other: Placebo	XWPharma	NULL	Not yet recruiting	40 Years	75 Years	All	70	Phase 2	NULL
10	NCT05083260 (ClinicalTrials.gov)	November 2021	23/9/2021	NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa	A Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetics Study in Parkinson's ...	Parkinson Disease	Drug: NE3107;Drug: placebo	BioVie Inc.	NULL	Not yet recruiting	30 Years	75 Years	All	40	Phase 1/Phase 2	NULL

First Previous1 2 3 4 5…102Next Last